In­novent Bi­o­log­ics sets a biotech record in Chi­na with $260M raise for PhI­II work

With the sub­stan­tial help of the Chi­nese gov­ern­ment, Shang­hai-based In­novent Bi­o­log­ics has lined up a record $260 mil­lion D round de­signed to take its first set of biosim­i­lars through late-stage test­ing as it builds out its man­u­fac­tur­ing op­er­a­tions. And com­pa­ny ex­ecs tell me that it will al­so help con­struct a pipeline of new drugs as In­novent lines up part­ners to mar­ket its ther­a­peu­tics out­side of Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER